BioNTech SE maintains a Strong Buy rating due to its promising late-stage oncology pipeline and strategic partnerships. Key drug candidates, gotistobart and pumitamig, have important trial data expected in 2026, supporting future growth. While the COVID-19 vaccine COMIRNATY faces sales pressure and lowered guidance, BioNTech's $19.28 billion cash reserve supports ongoing research and development. Despite a setback in an mRNA cancer immunotherapy study and higher operating costs, the company’s outlook remains positive for investors.
BioNTech halted its Phase 2 trial for a colorectal cancer vaccine after a Data Safety Monitoring Board found no efficacy, causing its stock to fall 8%. This setback also pressured Moderna's shares, which dropped 6%, despite its recent melanoma vaccin...
Moderna's stock jumped 11% with no new company news, driven by strong retail sentiment and trading momentum rather than fundamentals. Meanwhile, BioNTech rose only 2%, lagging behind both Moderna and the broader biotech sector, highlighting a growing...
Moderna shares fell 7% to $135.22 following a sharp rise to a record $176.66, as traders took profits after a 392% gain year-to-date. The pullback is orderly with no new company updates; the recent rally was driven by positive phase 3 melanoma trial ...
